Atara Biotherapeutics (ATRA) announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company’s previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATRA:
- Atara Biotherapeutics Reports Strong Q1 2025 Results
- Atara Biotherapeutics Announces $16M Stock Offering
- Buy Rating for Atara Biotherapeutics: Strategic Focus and Financial Positioning Ahead of Key FDA Meeting
- Atara Biotherapeutics Appoints New Board Members Amid Restructuring
- Atara Biotherapeutics Announces Major Workforce Reduction